New injection trial aims to tame deadly cholesterol in teens

NCT ID NCT07473843

Summary

This study is testing an experimental injection called zodasiran in adolescents aged 12 to 18 who have a rare, severe genetic cholesterol disorder called homozygous familial hypercholesterolemia (HoFH). The main goal is to see if the injection safely lowers their 'bad' LDL cholesterol over 12 months, even while they are on their current best cholesterol-lowering treatments. It is a single-arm study, meaning all participants will receive the active drug.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.